Browse by category

For patients living with mild-to-moderate obesity, newer obesity management medications (OMM) such as tirzepatide and semaglutide, appear to be valid alternatives to endoscopic bariatric procedures (EBP) and metabolic bariatric surgery (MBS), according to researchers from the Italian Obesity Society (Società Italiana dell'Obesità (SIO)). Their study reveals the results from a systematic review (SR) and a network meta-analysis (NMA) on randomised clinical trials (RCTs) compari

Phenomix Sciences has announced results from new research, presented at Obesity Week 2025, demonstrating the continued clinical utility of its MyPhenome test, backed by a proprietary machine-learning Genetic Risk Score (GRS), in predicting obesity and treatment outcomes across large and diverse patient populations. The studies, led by Mayo Clinic researcher and Phenomix co-founder Dr Andres Acosta, further validate the MyPhenome test's ability to predict patient response to G

Welcome to our regular round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have looked far and wide to give you an overview of papers including MBS is independently associated with improved survival in individuals aged 69 years and older, re-sleeve gastrectomy associated with significantly higher rates of serious perioperative complications, conversion to open in bariatric surgery associated with significant increased r

Apnimed has announced positive results from the Phase 2 FLOW study evaluating sulthiame, a differentiated, once-daily oral carbonic anhydrase inhibitor, in the treatment of obstructive sleep apnoea (OSA). The study demonstrated that sulthiame significantly improved important OSA metrics in adults with moderate to severe OSA. Sulthiame has a different mechanism of action from Apnimed's lead programme, AD109, with the potential to address other aspects of the pathophysiology of

Researchers from Singapore General Hospital (SGH) and National University of Singapore (NUS) have reported that using pulsed electromagnetic fields to stimulate muscle tissue and mimic the effects of exercise, could benefit patients with type 2 diabetes with excess abdominal fat. Magnetic mitohormesis device used to deliver low-dose PEMF. The device measures 50 cm (W) × 60 cm (L) × 110 cm (H), with a treatment chamber with an internal diameter of 26 cm and a depth of 50 cm. C

Treatment for obesity in the UK could become a two-tier system where the most vulnerable patients miss out altogether, obesity experts from King's College London and the Obesity Management Collaborative (OMC-UK) have warned. They stated that strict eligibility criteria means that only a small number of people will have access to the weight loss drug tirzepatide (Mounjaro) on the NHS, with those able to afford it paying privately for treatment. The researchers argue, in an edi

Scientists at the Keck School of Medicine of USC, working within the Southern California Superfund Research and Training Program for PFAS Assessment, Remediation and Prevention (ShARP) Center, have uncovered compelling evidence that exposure to perfluoroheptanoic acid (PFHpA), a lesser-known member of the PFAS family of ‘forever chemicals’, is linked to a significantly higher risk and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) in adolescents

A matched analysis from Uk researchers has provided preliminary evidence that metabolic and bariatric surgery (MBS) might be associated with improved survival in individuals aged 69 years and older with obesity, and can be performed with acceptable short-term risk in a specialist setting. The aim of the study was to assess the effect of MBS on long-term survival in patients with obesity aged 69 years and older compared with those of a similar age with obesity who did not unde

Welcome to our regular round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have looked far and wide to give you an overview of papers including bariatric surgery has become safer over time, higher hospital and surgeon MBS volumes were associated with lower short-term mortality, fewer complications and shorter hospital stays, pharmacologic management of post-bariatric hypoglycemia (PBH) shows promise but there is an urge

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity. The reviews, which examine the effects of three weight loss drugs known as GLP-1 receptor antagonists, have found that all three drugs result in clinically meaningful weight loss compared w